In order to get more accurate results, our search has the following Google-Type search functionality:
If you use '+' in front of a word, then that word will be present in the search results.
ex: Harry +Potter will return results with the word 'Potter'.
If you use '-' in front of a word, then that word will be absent in the search results.
ex: Harry -Potter will return results without the word 'Potter'.
If you use 'AND' between two words, then both of those words will be present in the search results.
ex: Harry AND Potter will return results with both 'Harry' and 'Potter'.
If you use 'OR' between two words, then bth of those words may or may not be present in the search results.
ex: Harry OR Potter will return results with just 'Harry', results with just 'Potter' and results with both 'Harry' and 'Potter'.
If you use 'NOT' before a word, then that word will be absent in the search results.
ex: Harry NOT Potter will return results without the word 'Potter'.
Placing '""' around words will perform a phrase search. The search results will contain those words in that order.
ex: "Harry Potter" will return any results with 'Harry Potter' in them, but not 'Potter Harry'.
Using '*' in a word will perform a wildcard search. The '*' signifies any number of characters. Searches can not start with a wildcard.
ex: Pot*er will return results with words starting with 'Pot' and ending in 'er'. In this case, 'Potter' will be a match.
|
|
|||
|
||||
OverviewMalignant melanoma is the most dangerous type of skin cancer. It accounts for about 75% of skin cancer deaths. Patients with advanced melanoma with dissemination to distant sites and visceral organs have a very poor prognosis, with a median survival time of 6 months and a 5-year survival rate of less than 5%. Over the past 40 years, no one drug or combination of drugs demonstrated any improvement on survival of metastatic melanoma patient. In the year 2011, FDA approved ipilimumab and Vemurafenib for the treatment of advanced melanoma. But both drugs only prolonged patients' life of 2-3 months. So the war to fight advanced melanoma is far from ending. In this book, the author and colleagues used classical approaches discovering and developing novel therapeutic agents for advanced melanoma. They identified several new classes of compounds which showed very potent in vitro activity against metastatic melanoma cells and in vivo activity on several animal models. They further optimized the lead compounds activity through a knowledge-based molecule design. They also identified the cellular target of these compounds and elucidated their mechanism of action in killing melanoma cells. Full Product DetailsAuthor: Zhao WangPublisher: LAP Lambert Academic Publishing Imprint: LAP Lambert Academic Publishing Country of Publication: United States Dimensions: Width: 15.20cm , Height: 1.10cm , Length: 22.90cm Weight: 0.281kg ISBN: 9783846520703ISBN 10: 3846520705 Pages: 188 Publication Date: 07 October 2011 Audience: General/trade , General Format: Paperback Publisher's Status: Active Availability: Not yet available  This item is yet to be released. You can pre-order this item and we will dispatch it to you upon it's release. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
Log In
Register/Sign Up
Customer Log In
